ABOUT US
We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.
Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.
QUALITY
As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.
WHO WE ARE
We deliver pharma products from Switzerland and from all over the world.
Our team in ELIXI International has a solid experience in the distribution of medical products.
History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.
NEWS
Luxturna (voretigene neparvovec), first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene recommended for authorisation by EMA
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for the gene therapy Luxturna…
New medicine to treat infections in adults: Vabomere, a combination of an antibiotic and new beta-lactamase inhibitor, addresses bacterial resistance.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Vabomere (meropenem trihydrate/vaborbactam), a…
Nerlynx, neratinib, a breast cancer medicine used to reduce the risk of the disease coming back in patients with early breast cancer who have had surgery.
Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who…
FDA approves Lumoxiti (moxetumomab pasudotox-tdfk), new kind of treatment for hairy cell leukemia
The U.S. Food and Drug Administration has approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult…
FDA approves first generic version of EpiPen
The U.S. Food and Drug Administration has approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for…
Cablivi (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
The European Commission has granted marketing authorization for Cablivi (caplacizumab) for the treatment of adults experiencing an episode of acquired…
Vyxeos (daunorubicin and cytarabine) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Jazz Pharmaceuticals plc has announced that the European Commission approved Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion for the…
Duzallo (allopurinol and lesinurad), for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone.
Duzallo is a medicine used in adults with gout to reduce high levels of uric acid in the blood. It…
FDA approves Oxervate (cenegermin) first drug for neurotrophic keratitis, a rare eye disease
The U.S. Food and Drug Administration has approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a…
FDA approves Galafold ( migalastat), a new treatment for a rare genetic disorder, Fabry disease
The U.S. Food and Drug Administration has approved Galafold (migalastat), the first oral medication for the treatment of adults with…
FDA approves Lenvima (lenvatinib) for unresectable hepatocellular carcinoma
On August 16, 2018, the Food and Drug Administration approved lenvatinib capsules (Lenvima, Eisai Inc.) for first-line treatment of patients…
CONTACT US
ELIXI International SA
Piazza Boffalora 4
6830 Chiasso / Switzerland
Tel: +41 91 682 20 40